**Pharmaceutical Products:** 55%
**Medical Devices:** 30%
**Research Services:** 15%

**TOP 3 Markets:**
**China:** 40%
**USA:** 25%
**Europe:** 20%

Shanghai Universal Biotech Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by medical devices and research services. The Chinese market is the largest single market for the company, followed by the USA and Europe. These markets are crucial for the company as they not only generate high revenues but also hold strategic importance for future growth and innovation.

**Production Sites:** Shanghai, China

Shanghai Universal Biotech Co., Ltd. mainly produces its products in Shanghai, China. The city is a significant center for biotechnology and pharmaceuticals in China, providing the company with access to a well-educated workforce and strong infrastructure.

In addition, depending on its growth strategy and market expansion, the company may consider establishing additional production facilities to better serve demand in other regions.

**Revenue Growth:** Estimated 18% (2025)

**Research and Development Investments:** 25% of revenue (2025)

Shanghai Universal Biotech Co., Ltd. pursues a growth strategy that is heavily based on innovation and research. The company invests significantly in research and development to develop new biotechnological products and enhance existing product lines. These investments account for approximately 25% of revenue, indicating a long-term commitment to innovation.

Another focus is on international expansion. The company plans to expand its presence in emerging markets to capitalize on the increasing demand for biotechnological solutions. Strategic partnerships and joint ventures are utilized to facilitate market entry and gain local expertise.

In addition, Shanghai Universal Biotech is leveraging digital transformation and automation to increase production efficiency and reduce operating costs. These measures are intended to strengthen the company's competitiveness in the global market.

**Main raw materials:** Chemical intermediates, pharmaceutical active ingredients (APIs)

**Countries of origin:** USA, Germany, India

Shanghai Universal Biotech Co., Ltd. mainly imports chemical intermediates and pharmaceutical active ingredients required for the production of their biotechnological products. The USA and Germany are important suppliers of highly specialized chemical compounds and APIs needed for research and development as well as drug manufacturing.

India also plays a significant role as a supplier of more cost-effective pharmaceutical active ingredients required in large quantities. This strategic sourcing of raw materials from different countries enables the company to manufacture both high-quality and cost-efficient products.

**Market Share:** 8% (estimated, 2026)
**R&D Expenses:** 12% of revenue (2025)
**Patent Portfolio:** 150 active patents (2025)

Shanghai Universal Biotech Co., Ltd. has gained a moderate competitive advantage in recent years, especially through its investments in research and development, which account for 12% of revenue. This demonstrates the company's commitment to developing innovative products and differentiating itself from competitors.

The company has an extensive patent portfolio with 150 active patents, highlighting its innovation capabilities and providing protection against imitators. The estimated market share of 8% indicates that the company operates in a highly competitive market, but maintains a solid position through its R&D strategy and patents.

To further strengthen its competitive advantage, the company could expand its market presence through strategic partnerships and international expansion. This would help increase market share and reduce dependence on individual markets.

**Institutional investor ownership:** Estimated at 40% (2026)
**Insider trades:** No significant transactions reported (2026)

The institutional investor ownership in Shanghai Universal Biotech Co., Ltd. is estimated to be around 40%. This demonstrates a strong confidence from institutional investors in the company, which is often seen as a positive signal for stability and growth potential.

In 2026, no significant insider transactions were reported. This could indicate that the management and other insiders are satisfied with the current valuation of the company or do not expect any significant changes in the company's strategy or performance.

**Market share of Shanghai Universal Biotech Co., Ltd.:** 3.5% (estimated for 2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 12.0%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 10.5%
3. **China National Pharmaceutical Group Corporation (CNPGC):** 9.0%
4. **Jiangsu Hengrui Medicine Co., Ltd.:** 7.5%
5. **CSPC Pharmaceutical Group Limited:** 6.0%
6. **Shanghai Fosun Pharmaceutical Group Co., Ltd.:** 5.5%
7. **Zhejiang Hisun Pharmaceutical Co., Ltd.:** 4.5%
8. **Shanghai Universal Biotech Co., Ltd.:** 3.5%
9. **Harbin Pharmaceutical Group Co., Ltd.:** 3.0%
10. **Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.:** 2.5%

**Moat of Shanghai Universal Biotech Co., Ltd.:**

Shanghai Universal Biotech Co., Ltd. has a moderate moat, mainly supported by specialized biotechnological innovations and a strong R&D department. The company specializes in niche products that offer an advantage in specific medical areas.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and a broader product range, the moat of Shanghai Universal Biotech is less pronounced. These larger companies benefit from economies of scale and a stronger market presence.

Nevertheless, Shanghai Universal Biotech could expand its moat in the future through continuous innovations and strategic partnerships. The focus on specialized biotechnological solutions offers growth potential, especially in emerging markets and specialized medical fields.

**Revenue Growth:** 18.5% (2025)
**R&D Expenses:** 12% of revenue (2025)
**Market Share in China:** 7% (2025)

Shanghai Universal Biotech Co., Ltd. achieved a revenue growth of 18.5% in 2025, attributed to strong demand for their biotechnological products and successful market expansion. The company consistently invests in research and development, with 12% of revenue allocated to R&D. This indicates a strong innovation capability that could be crucial for future growth.

The market share in China is 7%, representing a solid position in the domestic market. This offers potential for further growth, especially if the company expands its presence internationally. Additionally, the strong focus on R&D could lead to new product developments that further boost growth.

Overall, the company demonstrates positive fundamental data and a strategic orientation aimed at long-term growth. However, investors should also consider general market conditions and potential regulatory changes in the biotechnology sector.

**Dividend payment:** No dividend (as of 2026)

Shanghai Universal Biotech Co., Ltd. has not distributed any dividends to its shareholders so far. The company is in a growth phase and reinvests its profits in research and development as well as in expanding its business activities.

The reliability of the payout cannot currently be evaluated as there is no dividend history available. Investors should focus on other financial metrics and growth indicators to assess the financial health and future prospects of the company.